Study of MASH and cell changes in weight-loss surgery
Part of Digestive system clinical trials.
This study looks at a possible link between MASH (liver inflammation with fat buildup) and tiny cell structures that help liver cells work. Researchers want to understand this better in people having weight-loss surgery, where a small liver sample will be taken.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older).
- You are scheduled for weight-loss surgery (sleeve gastrectomy or gastric bypass).
- Your doctor suspects you have MASH (a type of fatty liver disease with inflammation) and plans to take a small piece of your liver during surgery.
- You do not have Hepatitis B or C, heavy drinking history, or other specific liver diseases.
- You are not pregnant, breastfeeding, or taking certain medications (like steroids, tamoxifen, or methotrexate) in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This study looks at how the body processes energy in people with fatty liver disease who are having weight-loss surgery. It may help doctors understand the disease better and could lead to better treatments.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.